Dihydroartemisinin inhibits the migration of esophageal cancer cells by inducing autophagy

XIAO CHEN1*, LAN-YING HE2*, SHU LAI3 and YAO HE1

1Department of Pharmacy, Chongqing Emergency Medical Center, Chongqing University Central Hospital, Chongqing 400014; 2Department of Gastroenterology, Tumor Hospital Affiliated to Chongqing University, Chongqing 400030; 3Department of Pharmacy, Jiulongpo District People’s Hospital of Chongqing, Chongqing 400050, P.R. China

Received December 26, 2019; Accepted June 23, 2020

DOI: 10.3892/ol.2020.11955

Abstract. Esophageal cancer (EC) is a complex gastrointestinal malignancy and its global incidence rate ranks 7th among all cancer types. Due to its aggressive nature and the potential for early metastasis, the survival rates of patients with EC are poor. Dihydroartemisinin (DHA) is the primary active derivative of artemisinin, and, as well as its use as an anti-malarial, DHA has also exhibited antitumor activity in various cancer models, such as cholangiocarcinoma, head and neck carcinoma, and hepatocellular carcinoma cells. However, the molecular mechanisms underlying the antitumor effect of DHA in the treatment of EC remains poorly understood. The results of the present study demonstrated that DHA significantly inhibited the migration of TE-1 and Eca-109 EC cells in a dose-dependent manner by activating autophagy. DHA treatment also significantly reversed epithelial-mesenchymal transition (EMT) by downregulating the EMT-associated markers, N-cadherin and vimentin, and upregulating the expression of E-cadherin. Mechanistically, DHA treatment decreased Akt phosphorylation and inhibited the Akt/mTOR signaling pathway, leading to the activation of autophagy. The levels of the autophagy-associated proteins were suppressed and DHA-mediated inhibition of migration in EC cells was reversed when an active form of Akt was overexpressed. In conclusion, the present study demonstrated the potential value of DHA in the treatment of EC, and revealed the underlying mechanism by which FDHA inhibits cellular migration.

Introduction

Esophageal cancer (EC) is a complex and heterogeneous gastrointestinal malignancy, which is ranked 7th with respect to incidence rate and 6th for overall mortality rate in 2018 for 36 cancer types, leading to >400,000 deaths each year, globally (1). Esophageal adenocarcinoma (EADC) and esophageal squamous cell carcinoma (ESCC) are the most common subtypes of EC (2). Cases of ESCC are primarily reported in lower income regions, such as South-Eastern and Central Asia, and the global incidence rate for ESCC is higher compared with that in EADC (3-5). There are various different approaches to treating EC, such as chemotherapy, radiotherapy, surgery and a combination treatment; however, the prognosis of patients with EC is still a challenge. Developing effective chemoprevention and chemotherapeutics to treat EC is difficult, as its etiology varies from person to person, such as tobacco and alcohol in North America and betel quid in India (6). Inefficient treatments result in poor 5-year survival rate and, even following advanced radical esophagectomy, the 5-year survival rate of patients with EC in 2018 is still <20% in China (7).

The primary cause of the low survival rate and poor prognosis for EC is early invasion and metastasis, which is a biological characteristic of cancer cells (8). The occurrence of invasion and metastasis involves complex multiple-step processes, numerous signaling pathways and regulation by transcription and growth factors, such as TGF-β, Snail, ZEB and bHLH (9-12), and the tumor microenvironment (13,14). Epithelial-mesenchymal transition (EMT) is an important process during tumor cell development and metastasis, which involves the transformation of polar epithelial cells into active mesenchymal cells, which can migrate freely between the cell stroma (15). EMT is marked by the loss of epithelial cell polarity and the acquisition of mesenchymal cell characteristics, with reduced expression of typical epithelial cell markers (such as E-cadherin) and increased mesenchymal cell markers (such as N-cadherin) (15). This phenotypic transformation releases tumor cells from intercellular connections, enabling non-invasive tumor cells to acquire invasive capacity, thereby promoting local invasion and distant tumor metastasis (16).

Numerous studies have indicated that EMT is regulated by autophagy, a critical cell survival process through which
aging organelles and misfolded proteins are degraded (17,18). Although previous studies (19,20) showed that dihydroartemisinin (DHA), the major active metabolite of artemisinin, might have an antitumor activity in various cancer models, whether DHA could regulate the EMT and migration of EC cells remains unknown. In the present study, a series of experiments were conducted to investigate the migration inhibition and underlying molecular mechanisms of DHA. Exploring the molecular mechanism could provide new perspectives and therapeutic targets for clinical therapy in patients with EC.

Materials and methods

Cell culture and reagents. The TE-1 and Eca109 EC cell lines were purchased from the Library of Typical Culture of the Chinese Academy of Sciences. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) in a 37°C incubator (95% air and 5% CO₂). DHA was dissolved in DMSO (both Sigma-Aldrich; Merck KGaA) to a final concentration of 20 µg/ml and stored at -20°C, in the dark until further use.

Immunofluorescence assay. EC cells were harvested using 0.25% trypsin-EDTA (HyClone; Cytiva) and seeded into a 24-well plate (1x10⁴ cells/well) to adhere overnight. The cells were then transfected with 800 ng pcDNA3.1-LC3-GFP, a plasmid expressing green fluorescent protein (GFP) and microtubule-associated protein 1A/1B-light chain 3 (LC3) (coding sequence of GFP and human LC3 were sub-cloned into pcDNA3.1(V790-20, Invitrogen; Thermo Fisher Scientific, Inc.), hereafter referred to as GFP-LC3) using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). The culture medium was replaced following 6 h of incubation at 37°C and 2 µg/ml DHA was added prior to incubation for a further 24 h. The samples were fixed with 1% Triton-X 100 buffer for 10 min, and the slides were subsequently stained with DAPI (Beyotime Institute of Biotechnology) for 5 min at room temperature.

Western blot analysis. A total of 1x10⁵ cells/well were inoculated into a 6-well plate and left to adhere at 37°C overnight. The cells were treated with various concentrations of DHA (1.25, 2.5 and 5.00 µg/ml) or 2 mmol/l 3-MA or a combined treatment for 24 h, following removal of the culture medium. The cells were then lysed on ice with radioimmunoprecipitation assay lysis buffer (Sangon Biotech Co., Ltd.) and the supernatant was collected following centrifugation (12,000 x g for 10 min) at 4°C. Protein concentration was determined using a bicinchoninic acid kit (Sangon Biotech Co., Ltd.). Equal amounts of protein (15 µg per well) were electrophoresed using 10% sodium dodecyl sulfate-polyacrylamide gels and transferred to PVDF membranes. The membranes were blocked with 1x EZ-Block A in PBS solution at 23°C for 1 h (Sangon Biotech Co., Ltd.). Subsequently, the membranes were incubated with LC3 (cat. no. L8918), sequestosome 1 (SQSTM1; cat. no. P0067), and β-actin antibodies (cat. no. SAB5600204) (all Sigma-Aldrich; Merck KGaA; dilution, 1:1,000), E-cadherin (cat. no. 31955S), N-cadherin (cat. no. 13116S), vimentin (cat. no. 5741S), p-mTOR (cat. no. 5536S), mTOR (cat. no. 2983S), AKT (cat. no. 4685S), phosphorylated (p)-Akt (cat. no. 13038S) (all Cell Signaling Technology, Inc.; dilution, 1:1,000) for 12 h at 4°C. Next, the membranes were incubated with HRP-labeled goat anti-rabbit IgG secondary antibodies (ZSGB-BIO; cat. no. ZB2301; dilution, 1:10,000) for 2 h at room temperature. The protein visualization was mediated by Western Blot Chemiluminescence HRP Substrate kit (Takara Bio, Inc.; cat. no. T7101A). The grey value was detected using ImageJ software v1.51d (National Institutes of Health).

Constitutively active (CA)-Akt overexpression assay. A total of 9x10⁵ cells were seeded in 6-well plates overnight, and 5 µg CA-Akt plasmid (cat. no. 14751; Addgene, Inc.) and pcDNA3.1 empty vector (cat. no. V790-20, Invitrogen; Thermo Fisher Scientific, Inc.) was transfected into the cells using Lipofectamine® 3000 (Invitrogen; Thermo Fisher Scientific, Inc.) when the cell fusion rate reached 85%. The cell culture was replaced and the cells was treated with DHA (2 µg/ml) or DMEM medium, 12 h later. Following 24 h of DHA treatment western blot analysis and wound-healing assays were performed as aforementioned.

Statistical analysis. The data are presented as the mean ± standard deviation. SPSS v19.0 (IBM Corp.) was used to conduct all statistical analyses. An unpaired student's t test was used to compare two groups or one-way ANOVA followed by Tukey’s post hoc test for multiple comparisons. P<0.05 was considered to indicate a statistically significant difference. GraphPad Prism v8.01 (GraphPad Software, Inc.) was used to produce the figures.
Results

DHA inhibits the migration of EC cells. To understand the effect of DHA on tumor invasion and metastasis, a cell migration assay was performed. The migratory capacity of Eca-109 and TE-1 EC cells was markedly inhibited by DHA. DHA-treated cells possessed a markedly larger wound width compared with those of the control group, and the width of the wound was concentration-dependent (Fig. 1A and C). For the Transwell assays, the number of migratory cells in the DHA group was significantly decreased in both Eca109 (P=0.006) and TE-1 (P=0.003) cells (Fig. 1B and D), which was consistent

Figure 1. DHA inhibits esophageal cancer cell migration in a concentration-dependent manner. (A) A total of $1 \times 10^6$ Eca-109 cells were seeded into 6-well plates and incubated overnight, following which the monolayers were scratched with 1-ml tips and the cells were cultured with media containing 3% FBS, and treated with 1, 2 or 5 µg/ml DHA for 24 h. Images of wound closure distances were captured 0 and 24 h post-treatment. Scale bar, 100 µm. (B) $2 \times 10^4$ Eca-109 cells were inoculated into Transwell chambers with serum-free medium, treated with 2 µg/ml DHA for 24 h, and then fixed and stained. Migration ability was measured using the mean number of cells in 20 visual fields. Scale bar, 50 µm. (C) A total of $1 \times 10^6$ TE-1 cells were seeded into 6-well plates and incubated overnight, the description of wound healing assay was similar as above. Scale bar, 100 µm. (D) $2 \times 10^4$ TE-1 cells were inoculated into Transwell chambers with serum-free medium and performed as above. Migration ability was measured using the mean number of cells in 20 visual fields. Scale bar, 50 µm. Data are represented as the mean ± standard deviation from 3 independent experiments. *P<0.05, **P<0.01 and ***P<0.001 vs. control. DHA, dihydroartemisinin.
with the results of the wound healing assay. These findings demonstrate that DHA can inhibit the migration of EC cells in a concentration-dependent manner.

**DHA activates autophagy in TE-1 and Eca109 cells.** To investigate the underlying mechanism by which DHA inhibits the migration of EC cells, its effects on the levels of proteins associated with autophagy, a crucial process for tumor cell survival under starvation and stress (13), were investigated. EC cells were transfected with a GFP-LC3 plasmid, and the puncta of LC3 were markedly increased following DHA treatment in both TE-1 (P=0.039) and Eca109 (P=0.012) cells (Fig. 2A). Western blot analysis also revealed a significant increase in LC3 protein expression, and a significant decrease in the

---

**Figure 2.** DHA induces autophagy in TE-1 and Eca-109 cells. (A) A total of 1x10⁶ cells were seeded into a 24-well plates and incubated overnight, and then transfected with an GFP-LC3 expression plasmid for 6 h. The cells were treated with 2 µg/ml DHA for 24 h, following which the cells were fixed and stained with DAPI. LC3 expression was analyzed using fluorescence microscopy, and the number of GFP-LC3 puncta per cell was determined using Image J. Yellow arrows indicate LC3 protein. Scale bar, 5 µm. A total of 1x10⁶ (B) Eca-109 and (C) TE-1 cells were seeded into 6-well plates and incubated overnight, and then treated with 2 µg/ml DHA for 24 h. Levels of autophagy-associated proteins were detected using western blot analysis, and the relative density was determined using ImageJ software. Data are presented as the mean ± standard deviation of 3 independent experiments. *P<0.05 and **P<0.01 vs. respective control. DHA, dihydroartemisinin; GFP, green fluorescent protein; LC3, microtubule-associated protein 1A/1B-light chain 3; SQSTM, sequestosome 1; ns, not significant.
protein levels of SQSTM, with increasing concentrations of DHA in both cell lines (Fig. 2B and C). These results demonstrate that DHA induces autophagy in EC cells.

**DHA inhibits the migration of EC cells by inducing autophagy.**

To determine whether DHA inhibited cell migration by activating autophagy, Transwell assays and western blot analysis were used to detect the migratory capacity and the levels of autophagy-associated proteins following treatment with the autophagy inhibitor 3-MA. In the Transwell assay, the cells of Eca-109 (P=0.007) and TE-1 (P=0.03) on the underside of the filter membrane were significantly lower in number compared with that in the control group, following treatment with DHA (Fig. 3A). However, this phenomenon was reversed, and the cell number significantly increased with co-treatment of 3-MA and DHA in both Eca-109 (P=0.003) and TE-1 (P=0.04) cells (Fig. 3A). These results indicate that the DHA-induced suppression of cell migration was weakened when autophagy was inhibited. The expression levels of the EMT markers and autophagy-associated proteins were also markedly altered; the protein levels of LC3 II and E-cadherin were significantly increased and SQSTM and N-cadherin levels decreased after DHA treatment alone. However, the expression levels of E-cadherin and LC3 II were decreased, while SQSTM and N-cadherin were increased following co-treatment with 3-MA and DHA (Fig. 3B and C). These results indicate that DHA inhibits the migration of TE-1 and Eca-109 cells by upregulating autophagy.

The Akt/mTOR signaling pathway is involved in the DHA-induced inhibition of EC cell migration. To determine how DHA regulates autophagy and subsequently inhibits cellular migration, the expression levels of the EMT-associated proteins, E-cadherin (21), N-cadherin (22) and vimentin (23) (important components of epithelial cell loss, polarization and mesenchymal transformation) were detected. Autophagy-associated proteins, LC3 and SQSTM were also detected, as well as the phosphorylation levels of Akt and mTOR (indicating the activated forms of these proteins), which negatively regulates autophagy (24-26). As shown in Fig. 4A and B, Akt and mTOR phosphorylation were inhibited by DHA treatment, accompanied by increasing LC3 and E-cadherin expression levels, and decreasing SQSTM, vimentin and N-cadherin expression, in both cell lines. To further determine the association between DHA and the Akt/mTOR signaling pathway, cells were transfected with CA-Akt to restore DHA-induced Akt/mTOR inhibition, and a wound-healing assay was conducted. As expected, the migratory abilities of the two EC cell lines were restored following co-treatment with DHA and CA-Akt, though migration was significantly
Figure 4. DHA induces autophagy via the Akt-mTOR signaling pathway. A total of 1x10^6 (A) Eca-109 and (B) TE-1 cells were seeded into 6-well plates to adhere overnight, and then treated with 2 µg/ml DHA for 24 h. Levels of autophagy- and EMT-associated proteins were detected using western blot analysis and the relative density was analyzed using ImageJ software. Furthermore, 1x10^6 (C) Eca-109 and (D) TE-1 cells were seeded into 6-well plates overnight and then transfected with CA-Akt. The cell monolayers were scratched with 1-ml tips after 12 h, subsequently cultured with medium containing 3% FBS, and then treated with 2 µg/ml DHA. Images of wound closure distances were captured after DHA treatment at 0 and 24 h. Scale bar, 100 µm. Following 12 h of transfection with CA-Akt, (E) Eca-109 and (F) TE-1 cells were treated with 2 µg/ml DHA for 24 h, and the levels of autophagy- and EMT-associated proteins were determined using western blot analysis and the relative densities were analyzed using ImageJ software. Data are presented as the mean ± standard deviation of 3 independent experiments. *P<0.05 and **P<0.01. DHA, dihydroartemisinin; p, phosphorylated, LC3, microtubule-associated protein 1A/1B-light chain 3; SQSTM, sequestosome 1; CA, constitutively active; EMT, epithelial-mesenchymal transition; -, without; +, with.
decreased by DHA treatment alone (Fig. 4C and D). The results of western blot analysis were consistent with those of the wound-healing assay; in cells transfected with CA-Akt and treated with DHA, the protein levels of p-Akt, SQSTM and N-cadherin were significantly increased compared with DHA treatment alone (Fig. 4E and F). These data indicate that DHA activates autophagy by inhibiting the phosphorylation of Akt, and subsequently suppressing the migration of TE-1 and Eca-109 cells.

Discussion

DHA, one of the primary derivatives of artemisinin, has well established anti-malarial effects and has recently been reported as a potential antitumor compound (27). An increasing amount of evidence has suggested that DHA can inhibit proliferation by promoting cell cycle arrest and apoptosis in human hepatic carcinoma (28), cholangiocarcinoma (29), cervical cancer (30) and tongue squamous carcinoma cells (31). Moreover, DHA can also prevent the migration of malignant tumor cells, such as lung cancer (32) and ovarian carcinoma cells (33). The antitumor activity of DHA in EC cells was also shown to affect apoptosis, the cell cycle and glycosylation (29,34-38); however, to the best of our knowledge, its inhibitory effects on cell migration have not previously been reported.

EC is a common malignancy of the digestive tract, which ranks 7th among 36 cancer types in occurrence worldwide in 2018. The prognosis of patients with EC is poor following esophagectomy, due to the metastasis and invasion of EC cells (8). EMT is a precursor of tumor metastasis, which comprises in the loss of cell polarity and the acquiring of mesenchymal cell characteristics (39). In the present study, DHA was shown to markedly inhibit EC cell migration, with reduced N-cadherin and increased E-cadherin protein expression. Wound-healing and Transwell assays consistently demonstrated that the migration of TE-1 and Eca-109 cells was inhibited following DHA treatment. Further investigations into the underlying mechanism of DHA revealed that migration inhibition was mediated by autophagy, and this was reversed following co-treatment with DHA and the autophagy inhibitor, 3-MA.

As a ‘self-eating’ process, autophagy serves a crucial role in cell survival via the degradation of aging organelles or misfolded proteins (40). An increasing number of studies have demonstrated that autophagy is associated with EMT (41,42); however, the means by which autophagy regulates EMT are not completely clear. Li et al (43) found that autophagy was induced in hepatoma cells treated with serum-free Hank’s medium for 6 h, and that the expression of EMT and mesenchymal markers were decreased and increased, respectively. On the other hand, Park et al (44) demonstrated that SQSTM formed large aggresome-like induced structures (ALISs). Ubiquitination protease aggregates are generally rapidly degraded, whereas proteins bound by ALISs have a longer half-life. Transcription factors mediating EMT can also be protected in this way (45,46). In the present study, DHA induced autophagy, subsequently suppressing EMT and cellular migration via the Akt/mTOR signaling pathway. DHA treatment in TE-1 and Eca-109 cells also inhibited the phosphorylation of Akt. In addition, the levels of p-Akt were significantly increased in the two cell lines, in cells transfected with a constitutively active form of Akt and active Akt restored the decreased expression level of SQSTM in DHA-treated cells. However, the underlying regulation mechanisms of DHA on Akt/mTOR pathway remains unclear, elucidating the molecular mechanisms of these processes requires further investigation.

This study was aimed to investigate the antitumor activity of DHA in esophagus cancer cells. The results demonstrated that DHA could inhibit the migration capacity of Eca109 and TE-1 cells through inducing autophagy. Exploring the underlying mechanism provides new perspectives for clinical cancer therapy. However, some limitations remain in the present study. The cells were cultured with medium containing 3% FBS to maintain cell survival rather than without FBS in wound healing assay, which may influence the accuracy of this result. Furthermore, the detailed molecular mechanisms between DHA and AKT/mTOR pathway are still unknown.

In conclusion, the results of the present study demonstrated that DHA inhibits the migration of EC cells by inducing Akt/mTOR axis-mediated cytostatic autophagy. These findings may provide novel insights into the migration inhibiting activity of DHA and provide evidence to support the potential use of DHA in the clinical treatment of EC.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed in this study are included in this published article.

Authors' contributions

YH conceived and designed the study. XC and LYH prepared the experimental materials and equipment. XC, LYH and SL performed the experiments and acquired the data. XC and LYH analyzed and interpreted the data. XC, LYH and SL drafted the manuscript and revised it critically for important intellectual content. SL and YH summarized and analyzed the data generated or acquired in this study. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018.

2. Arnold M, Soerjomataram I, Ferlay J and Forman D: Global incidence of oesophageal cancer by histological subtype in 2012. Gut 64: 381-387, 2015.

3. Abbasi BA, Iqbal J, Ahmad R, Bibi S, Mahmod T, Kanwal S, Bashir S, Gul F and Hameed S: Potential phytochemicals in the prevention and treatment of esophageal cancer: A green therapeutic approach. Pharmacol Rep 71: 644-652, 2019.

4. Zhang Y: Dihydroartemisinin in esophageal cancer. World J Gastroenterol 19: 5598-5606, 2013.

5. Napier KJ, Scheerer M and Misra S: Esophageal cancer: A review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol 6: 112-120, 2014.

6. Mir MM and Dar NA: Esophageal cancer in kashmir (India): An enigma for researchers. Int J Health Sci (Qassim) 3: 71-85, 2009.

7. Wong M, Hamilton W, Whiteman DC, Jiang JY, Qiao Y, Fung F, Wang H, Chiu P, Ng E and Wu J, et al: Global Incidence and mortality of oesophageal cancer and their correlation with socioeconomic indicators temporal patterns and trends in 41 countries. Sci Rep 8: 4522, 2018.

8. Nan L, Wei J, Jacko AM, Culely MK, Zhao J, Natarajan V, Ma H and Zhao Y: Cross-talk between lysophosphatidic acid receptor 1 and tropomyosin receptor kinase A promotes lung epithelial cell migration. Biophys J 107: 729-235, 2016.

9. Tripathi V, Shin JH, Stuelten CH and Zhang YE: TGF-β-induced alternative splicing of TAK1 promotes EMT and drug resistance. Oncogene 38: 3185-3200, 2019.

10. Ota I, Masui T, Kurihara M, Yook JI, Mikami S, Kimura T, Shimada K, Konishi N, Yane K and Yamano T and Kitahara T: Snail-induced EMT promotes cancer stem cell-like properties in head and neck cancer cells. Oncol Rep 35: 261-266, 2016.

11. Mooney SM, Talebian V, Jolly MK, Jia D, Gromala M, Levine H and McConkey BJ: The GRHL2/ZEB feedback loop—a key axis in the regulation of EMT in breast cancer. J Cell Biochem 118: 2559-2570, 2017.

12. Cano A and Portillo F: An emerging role for class I BHLH E2-2 proteins in EMT regulation and tumor progression. Cell Adh Migr 4: 56-60, 2010.

13. Gao FX, Wu J and Ren DL: Effect of epithelial-to-mesenchymal transition on biological activity of NK cells in esophageal squamous cell carcinoma. Sichuan Da Xue Xue Bao Yi Xi Ban 50: 40-47, 2019 (In Chinese).

14. Yokozaki H, Koma YI, Shigeoka M and Nishio M: Cancer as a tissue: The significance of cancer-stromal interactions in the development, morphogenesis and progression of human upper digestive tract cancer. Pathol Int 68: 334-352, 2018.

15. Liu S, Huang P, Gan J, Ling X, Du X, Liao Y, Li L, Meng Y, Li Y and Bai Y: Dihydroartemisinin represses esophageal cancer cell proliferation and migration by inhibiting the anti-tumor effects of photodynamic therapy via down-regulating pyruvate kinase M2. Eur J Pharmacol 854: 232-239, 2019.

16. Li Y, Sui H, Wei XL, Liu L, Ren J, Liu Y, Huang P, Du X, Du J and Bai Y: Dihydroartemisinin increases the sensitivity of photodynamic therapy via NF-κB/HIF-1α/VEGF pathway in esophageal cancer cell lines in vitro and in vivo. Cell Physiol Biochem 48: 2035-2045, 2018.

17. Jiang C, Li S, Li Y and Bai Y: Anticancer effects of dihydroartemisinin on human esophageal cancer cells in vivo. Anat Cell Pathol (Amst) 2018: 8759745, 2018.

18. Li S, Huang P, Gan J, Ling X, Du X, Liao Y, Li L, Meng Y, Li Y and Bai Y: Dihydroartemisinin represses esophageal cancer glycolysis by down-regulating pyruvate kinase M2. Eur J Pharmacol 854: 232-239, 2019.

19. Yoshida Y, Sui H, Wei XL, Liu L, Ren J, Liu Y, Huang P, Du X, Du J and Bai Y: Dihydroartemisinin represses esophageal cancer cell proliferation and migration by inhibiting the anti-tumor effects of photodynamic therapy via down-regulating pyruvate kinase M2. Eur J Pharmacol 854: 232-239, 2019.

20. Li Y, Sui H, Zhong J, Wei L, Liu L, Ren J, Liu Y, Huang P, Du X, Du J and Bai Y: Dihydroartemisinin increases the sensitivity of photodynamic therapy via NF-κB/HIF-1α/VEGF pathway in esophageal cancer cell lines in vitro and in vivo. Cell Physiol Biochem 48: 2035-2045, 2018.

21. Jiang C, Li S, Li Y and Bai Y: Anticancer effects of dihydroartemisinin on human esophageal cancer cells in vivo. Anat Cell Pathol (Amst) 2018: 8759745, 2018.

22. Zhang CZ, Zhang H, Yun J, Chen GG and Lai PB: Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochem Pharmacol 83: 1278-1289, 2012.

23. Thongchot S, Vidoni C, Ferarelli A, Loirome W, Yongyanit P, Namwat N and Isidoro C: Dihydroartemisinin induces apoptosis and autophagy-dependent cell death in cholangiocarcinoma through a DAPK1-BCLIN1 pathway. Mol Carcinog 57: 1735-1750, 2018.

24. Li X, Bai Q, Liu Y, Yue Q, Chen P, Li J, Zhang H, Ying H, Ding Q, Song H, et al: Dihydroartemisinin selectively inhibits PDGF-Rα-positive ovarian cancer growth and metastasis through inducing degradation of PDGF-Rα protein. Cell Discov 3: 17042, 2017.

25. Shi X, Wang L, Li X, Bai J, Li J, Li S, Wang Z and Zhou M: Dihydroartemisinin induces autophagy-dependent death in human tongue squamous cell carcinoma cells through DNA double-strand break-mediated oxidative stress. Oncotarget 8: 45981-45993, 2017.

26. Jiang J, Geng G, Yu X, Liu H, Gao J, An H, Cai C, Li N, Shen D, Wu X, et al: Repurposing the anti-malarial drug dihydroartemisinin suppresses metastasis of non-small-cell lung cancer via inhibiting NF-kappaB/GLUT1 axis. Oncotarget 7: 87271-87283, 2016.

27. Im E, Yeo C, Lee JJ and Lee EO: Dihydroartemisinin induced caspase-dependent apoptosis through inhibiting the specificity protein 1 pathway in hepatocellular carcinoma SK-Hep-1 cells. Life Sci 192: 296-292, 2018.

28. Li Y, Sui H, Zhong J, Wei L, Liu L, Ren J, Liu Y, Huang P, Du X, Du J and Bai Y: Dihydroartemisinin inhibits the anti-tumor effects of photodynamic therapy via down-regulating pyruvate kinase M2 in esophageal squamous cell carcinoma SK-HeP-1 cells. J Pharmacol 854: 232-239, 2019.

29. Yoshida Y, Sui H, Wei XL, Liu L, Ren J, Liu Y, Huang P, Du X, Du J and Bai Y: Dihydroartemisinin increases the sensitivity of photodynamic therapy via NF-κB/HIF-1α/VEGF pathway in esophageal cancer cell lines in vitro and in vivo. Cell Physiol Biochem 48: 2035-2045, 2018.

30. Jiang C, Li S, Li Y and Bai Y: Anticancer effects of dihydroartemisinin on human esophageal cancer cells in vivo. Anat Cell Pathol (Amst) 2018: 8759745, 2018.

31. Li S, Huang P, Gan J, Ling X, Du X, Liao Y, Li L, Meng Y, Li Y and Bai Y: Dihydroartemisinin represses esophageal cancer cell proliferation and migration by inhibiting the anti-tumor effects of photodynamic therapy via down-regulating pyruvate kinase M2. Eur J Pharmacol 854: 232-239, 2019.
42. Feng H, Zhao X, Guo Q, Feng Y, Ma M, Guo W, Dong X, Deng C, Li C, Song X, et al: Autophagy resists EMT process to maintain retinal pigment epithelium homeostasis. Int J Biol Sci 15: 507-521, 2019.
43. Li J, Yang B, Zhou Q, Wu Y, Shang D, Guo Y, Song Z, Zheng Q and Xiong J: Autophagy promotes hepatocellular carcinoma cell invasion through activation of epithelial-mesenchymal transition. Carcinogenesis 34: 1343-1351, 2013.
44. Park S, Ha SD, Coleman M, Meshkibaf S and Kim SO: p62/SQSTM1 enhances NOD2-mediated signaling and cytokine production through stabilizing NOD2 oligomerization. PLoS One 8: e57138, 2013.
45. Qiang L, Zhao B, Ming M, Wang N, He TC, Hwang S, Thorburn A and He YY: Regulation of cell proliferation and migration by p62 through stabilization of Twist1. Proc Natl Acad Sci USA 111: 9241-9246, 2014.
46. Qiang L and He YY: Autophagy deficiency stabilizes TWIST1 to promote epithelial-mesenchymal transition. Autophagy 10: 1864-1865, 2014.